Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02280044 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Rifaximin in Preventing Campylobacteriosis
A Phase 2 study, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02280044 is a Phase 2 study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 30 participants.
The verdict
NCT02280044, a Phase 2 study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is a randomized, double-blinded, placebo-controlled, in-patient trial evaluating the prophylactic efficacy of rifaximin against campylobacteriosis following challenge with C. jejuni.
Interventions
- BIOLOGICAL Rifaximin intervention
- BIOLOGICAL Placebo intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02280044
The ClinicalTrials.gov registry entry for NCT02280044 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins Bloomberg School of Public Health, which has 187 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rifaximin intervention is the first listed.
NCT02280044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02280044 about?
NCT02280044 is a clinical study titled "Efficacy of Rifaximin in Preventing Campylobacteriosis". This study is a randomized, double-blinded, placebo-controlled, in-patient trial evaluating the prophylactic efficacy of rifaximin against campylobacteriosis following challenge with C. jejuni.
What is the current status of trial NCT02280044?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-10. Estimated completion is 2016-08-09.
What interventions are being tested in trial NCT02280044?
The interventions under investigation include: Rifaximin intervention (BIOLOGICAL), Placebo intervention (BIOLOGICAL).
Who is sponsoring clinical trial NCT02280044?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.